ABSTRACT
It was established that the administration of an aqueous solution of bis(µ-tartrato)di(µ-hydroxy) germanate (IV) triethanolammonium to animals daily for 2 months at a dose of the active substance of 10 mg/kg of the animal's weight leads to inhibition of the total activity of the alkaline phospholipase A2 of mononuclear cells. The results of the study can be used to correct lipid metabolism in the development of disorders in hyperlipidemia. This makes it possible to expand the scope of use of the studied substance and create new pharmaceuticals based on bis(µ-tartrato)di(µ-hydroxy) germanate (IV) triethanolammonium prevent and inhibit the development of hyperlipidemia.
Subject(s)
Ethanolamines/pharmacology , Hyperlipidemias/drug therapy , Organometallic Compounds/pharmacology , Phospholipase A2 Inhibitors/pharmacology , Phospholipases A2/metabolism , Animals , Cholesterol/blood , Germanium/chemistry , Germanium/pharmacology , Hyperlipidemias/enzymology , Hyperlipidemias/pathology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/enzymology , Lipid Metabolism/drug effects , Lipids/blood , Phospholipases A2/blood , RabbitsABSTRACT
The influence of biologically active substance germatranol in low and very low doses on the respiration rate and the content of reactive oxygen species (ROS) in wheat roots under conditions of high stress was investigated. The results showed that solutions of the studied substance in concentrations of from 105 M to 1010 M (depending on the temperature) increase the thermotolerance of wheat germs and affect the ROS content and respiration rate. It is assumed that germatranol can have a positive impact on plant growth and development and act as antioxidants in plant cells.
Subject(s)
Germination/drug effects , Heat-Shock Response/drug effects , Oxygen Consumption/drug effects , Plant Roots/growth & development , Seedlings/growth & development , Triticum/growth & development , Reactive Oxygen Species/metabolismABSTRACT
The authors studied in vitro the immunopharmacodynamics of the new silantrane mival. It was shown that mival possessed mitogenic effects on mononuclear cell proliferation in donors and patients with rheumatoid arthritis. The drug stimulated mononuclear cell proliferation, by acting selectively on T lymphocytes, enhancing T-cell growth lymphokine production, T-suppressor cell activity, and inhibiting prostaglandin E2 production.
